Teverelix Evaluated in Advanced Prostate Cancer

NCT04693507 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Adenoma

Interventions

DRUG: teverelix TFA 120 mg
DRUG: teverelix TFA 180 mg

Sponsor

Antev Ltd.